2261results about "Glycosyltransferases" patented technology

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

The invention belongs to the technical field of gene engineering, and particularly relates to mutants of murA and ygeA genes and application of the mutants in production of human milk oligosaccharides. According to the invention, murA and ygeA genes of escherichia coli are edited by using a gene editing technology, so that a genetic engineering chassis strain carrying murA and ygeA mutants is obtained. Further, the chassis strain is applied to the construction process of production strains of LNT II, LNnT, LNT, 3 '-SL and 6'-SL, and the yield of the LNT II, the LNnT, the LNT, the 3 '-SL and the 6'-SL is further increased.

The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

The present invention relates to methods of immunomodulation and treating patients having solid tumors with antibodies that specifically bind CD38.

Provided are a salt tolerance related protein GmXTH32 having an amino acid sequence as shown in sequence 2, and a related biomaterial and use thereof. The use comprises: improving salt tolerance of plants and / or preparing products for improving salt tolerance of plants; and improving the survival rate of plants under salt stress and / or preparing products for improving the survival rate of plants under salt stress. The salt tolerance of plants can be changed by regulating and controlling the expression level of a coding gene of the protein in the plants, and the salt tolerance of the plants can be improved by reducing the expression level of the coding gene of the protein.

The invention discloses a glycosyl transferase UGTSL2 mutant. The UGTSL2 mutant is subjected to any one or more of the following mutations on the basis of an amino acid sequence as shown in SEQ ID NO.1: the 23rd amino acid is mutated from N to E; the 41st amino acid is mutated from R to P; the 91st amino acid is mutated from H to K; the 95th amino acid is mutated from K to D; the 123 amino acid is mutated from E to P; the 136th amino acid is mutated from L to F; the 151st amino acid is mutated from R to F; the 124 amino acid is mutated from H to E; the 168th amino acid is mutated from V to Y; the 198 amino acid is mutated from C to K; the 202nd amino acid is mutated from T to E; the 217th amino acid is mutated from W to K; the 225th amino acid is mutated from P to L; the 226 amino acid is mutated from F to V; the 285th amino acid is mutated from A to V; and the 333rd amino acid is mutated from I to V and the like.

The invention relates to the technical field of microbial genetic engineering, in particular to a sialyltransferase mutant with high yield of 3 '-sialyllactose as well as a construction method and application of the sialyltransferase mutant. The sialyltransferase mutant is selected from at least one of an NST protein or a mutant and a 406 NST protein or a mutant, the NST protein comprises an amino acid residue site in a sequence as shown in SEQ ID NO.1, and the 406 NST protein comprises an amino acid sequence in a sequence as shown in SEQ ID NO.2. The sialyltransferase mutant has the advantages that the sialyltransferase mutant can be used for preparing sialyltransferase, and the sialyltransferase mutant can be used for preparing sialyltransferase. The invention also provides a nucleic acid molecule containing the sialyltransferase mutant, an expression cassette, a recombinant vector, a recombinant microorganism and a construction method and application thereof, and has great significance in large-scale industrial production of 3-sialyllactose.

The invention relates to a gene modified cell and a method for producing fucosyllactose by using the gene modified cell, in particular to a kluyveromyces kluyveromyces gene modified cell and application thereof, and belongs to the technical field of biological gene engineering. The present invention provides a genetically modified cell comprising a recombinant nucleic acid sequence encoding a polypeptide having an [alpha]-1, 2-fucosyltransferase polypeptide ([alpha]-1, 2-fucosyltransferase) activity. The alpha-1, 2-fucosyltransferase polypeptide includes, but is not limited to, polypeptides having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% identical amino acid sequences with the amino acid sequences of SEQ ID NO: 1-25. According to the gene modified cell, the fucosyllactose synthesis capability of an original strain is improved.

The invention relates to a halophilic bacterium plasmid based on a sucrose lethal gene. The invention also provides a method for obtaining engineering halophilic bacteria without plasmids by using the halophilic bacteria plasmids.

The invention discloses an N-acetylglucosamine transferase AcetRS-R346D and an application thereof, and belongs to the technical field of functional enzymes. And the amino acid sequence of the N-acetylglucosamine transferase AcetRS-R346D is as shown in SEQ ID NO. 3. The invention further discloses the application of the N-acetylglucosamine transferase AcetRS-R346D in the preparation of the chitosan oligosaccharide. The N-acetylglucosamine transferase AcetRS-R346D disclosed by the invention is obtained by carrying out mutation modification on the N-acetylglucosamine transferase AcetRS, and can be used for producing the chitosan oligosaccharide with the polymerization degree of 4 to 7, especially (GlcNAc) 7. The product spectrum of the N-acetylglucosamine transferase is widened, and the N-acetylglucosamine transferase can be used for preparing high-polymerization-degree chitosan oligosaccharide and has a wide application prospect.

The invention belongs to the technical field of chondroitin sulfate biosynthesis, and discloses a recombinant strain for high-yield chondroitin sulfate, application of the recombinant strain and a preparation method of the chondroitin sulfate. The recombinant strain provided by the invention can be used for simultaneously expressing UDP-glucosamine isomerase, UDP-glucose dehydrogenase, chondroitin polymerase, glucosamine synthetase, phosphoglucosamine mutase, UDP-N-acetylglucosamine pyrophosphorylase, glucose-6-phosphate isomerase and glucose phosphate mutase; according to the present invention, glucose-1-phosphate uridyl transferase, ATP sulfonase, sulfotransferase, pyruvate kinase and APS kinase are adopted, and the enzyme molecules are matched with the original carbon metabolism pathway in the recombinant strain cell to jointly form the enzyme-linked pathway having the efficient CSA synthesis ability, such that the high-yield and high-purity preparation of the CSA can be achieved; the method has the advantages of simple operation, high biological safety of the obtained product, easy realization of large-scale production and the like, and has a good application prospect.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload inhibits expression or activity of DUX4. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide or RNAi oligonucleotide.

Aspects of the disclosure relate to complexes comprising a muscle-targeting agent covalently linked to a molecular payload. In some embodiments, the muscle-targeting agent specifically binds to an internalizing cell surface receptor on muscle cells. In some embodiments, the molecular payload promotes the expression or activity of a functional dystrophin protein. In some embodiments, the molecular payload is an oligonucleotide, such as an antisense oligonucleotide, e.g., an oligonucleotide that causes exon skipping in a mRNA expressed from a mutant DMD allele.

The invention provides a fucosyl transferase polypeptide, which can be applied to the synthesis of human milk oligosaccharides (HMOs), and belongs to the technical field of enzyme engineering. The fucosyltransferase polypeptide provided by the invention comprises polypeptides with at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% and 100% same amino acid sequences as polypeptides shown in amino acid sequences such as SEQ ID NO: 1-25. According to the transferase polypeptide disclosed by the invention, the specificity of a polypeptide catalytic substrate is also improved while the ability of the polypeptide as shown in SEQ ID NO: 1 to catalyze and synthesize 2 '-FL is improved.

A mammalian or avian cell line that expresses high levels of human influenza virus receptors is provided. In one embodiment, the cell line supports human influenza virus, e.g., human A / H3 influenza virus, isolation and growth much more effectively than corresponding conventional (unmodified) cells or in corresponding human virus receptor-overexpressing cells, and the propagated viruses may maintain higher genetic stability than in the corresponding cells.

The invention discloses a light-driven synthetic flora and application thereof. The light-driven synthetic flora comprises phototrophic bacteria and heterotrophic bacteria, the phototrophic bacteria are genetically modified synechococcus slender, and the gene modification comprises construction and expression of heterologous sucrose permease, glyceraldehyde dehydrogenase and sucrose synthase in the synechococcus slender; and the heterotrophic bacteria are the P.adami. According to the light-driven synthetic flora disclosed by the invention, carbon dioxide is converted into cane sugar through photosynthesis of phototrophic bacteria, and the cane sugar is secreted out of cells to provide a carbon source for heterotrophic bacteria; carrying out cell growth and polyhydroxyalkanoate synthesis on the heterotrophic bacteria by using cane sugar; therefore, the light-driven synthetic flora provided by the invention can realize direct conversion of carbon dioxide into polyhydroxyalkanoate without additional carbon sources, has the advantage of environmental friendliness, and provides a new economical and feasible scheme and approach for production of polyhydroxyalkanoate.

The invention discloses a genetically engineered bacterium for producing uridine diphosphate glucose as well as a construction method and application of the genetically engineered bacterium, and belongs to the technical field of genetic engineering. The following genes are overexpressed in the genetically engineered bacterium: a pyrimidine nucleoside operon gene, a carbamyl phosphate synthetase gene, an aspartate carbamyl transaminase gene, an orotic acid phosphoribose transferase gene, a phosphoribose pyrophosphate synthase gene, a uridylate kinase gene and a glucophosphate mutase gene. A uridine triphosphate glucose-1-phosphate uridine group transferase gene; the genetically engineered bacterium does not express the following genes: a purine nucleotide repressor protein gene, a deoxyribonucleoside triphosphate reductase gene, a nucleoside triphosphate pyrophosphohydrolase gene, a cytidine triphosphate synthase gene, a pyrimidine nucleotidase gene, a nucleotidase gene, an ornithine carbamoyltransferase gene, a UDPG dehydrogenase gene and a lacI repressor protein gene. The genetically engineered bacterium can be used for efficiently synthesizing UDPG by taking glucose as a substrate.

Glycosyltransferase UGT76G1 and UGT91C1 mutants and a method for catalytic synthesis of rebaudioside A, D, and M by using same, pertaining to the technical field of biocatalytic synthesis. The glycosyltransferase UGT76G1 mutant can effectively synthesize rebaudioside A using stevioside STV as a substrate. The glycosyltransferase UGT91C1 mutant is obtained by mutation screening of wild-type glycosyltransferase UGT91C1, has higher enzyme activity and catalytic rate, and can effectively synthesize rebaudioside D using rebaudioside A as a substrate. The glycosyltransferase UGT76G1 mutant can also be obtained by mutation and subsequent screening of glycosyltransferase UGT76G1, has higher catalytic activity, and can effectively synthesize rebaudioside M using rebaudioside D and UDPG as substrates.

The invention discloses an L-histidine transporter mutant and a method for increasing the yield of L-histidine, and the mutant has any one mutation of I20A, V28L, I20A-V28L and I20A-V21L-T28S relative to an escherichia coli wild type yeaS. The yield of the L-histidine of the recombinant escherichia coli containing the yeaS mutant protein is remarkably increased, it is indicated that the yeaS mutant protein and the coding gene of the yeaS mutant protein can be used for increasing the yield of the L-histidine, and the mutant can lay a good foundation for industrial efficient production of the L-histidine and downstream metabolites.

Provided is a glycosyltransferase UGTSL2 mutant, which is produced through any one or more selected from the group consisting of mutations based on an amino acid sequence shown in SEQ ID NO: 1. Also provided is a glycosyltransferase mutant, which is the following A1) or A2): A1) a protein produced through an amino acid residue substitution in an amino acid sequence shown in SEQ ID NO: 66, where the protein has an identity of 90% or more with and the same function as the amino acid sequence shown in SEQ ID NO: 66; and A2) a fusion protein produced by linking a tag to an N-terminus and / or a C-terminus of the protein in the A1).

Provided herein, inter alia, is an engineered non-plant cell that produces a hyoscyamine alkaloid product, a precursor of a hyoscyamine alkaloid product, or a derivative of a hyoscyamine alkaloid product. Also described is a method for producing a scopolamine alkaloid, a precursor of a scopolamine alkaloid product, or a derivative of a scopolamine alkaloid product using a cell.

The invention relates to the technical field of biocatalytic synthesis. The invention particularly relates to a glycosyl transferase mutant and a method for catalytically synthesizing rebaudioside M2 by using the glycosyl transferase mutant. The invention relates to a glycosyl transferase mutant, which is characterized in that the glycosyl transferase mutant is A1) or A2): A1) is a protein which is obtained by substitution of amino acid residues on an amino acid sequence as shown in SEQ ID NO.20, has more than 90% of identity with an original protein and has the same function with the original protein; a2) a fusion protein obtained by connecting a tag to the N end and / or C end of A1).

The invention relates to the technical production field of metabolic engineering and genetic engineering, and particularly provides a uracil production strain as well as a construction method and application thereof. According to the strain, a uridine kinase gene udk is knocked out on an E.coli W3110 genome, and meanwhile, a T7RNA polymerase gene is integrated; the uridine monophosphate kinase gene pyrH is weakened; the method comprises the following steps: overexpressing a carbamyl phosphate synthetase gene carAB, a ribose phosphate pyrophosphate kinase gene prsA, a pyrimidine-5 '-nucleoside enzyme gene ppnN, UMP phosphohydrolase genes umpH and umpG, a ribonucleoside hydrolase 1 gene rihA and a glutamine synthetase gene glnA; an orotic acid nucleoside monophosphate decarboxylase gene pyrF and an orotic acid ribosyltransferase gene pyrE of wild type bacillus subtilis B.subtilis 168 are introduced in a heterologous manner, so that an orotate nucleoside monophosphate decarboxylase gene pyrF and an orotate ribosyltransferase gene pyrE are obtained. The safe, efficient and low-cost production of the uracil is realized.

The present invention provides a fucosyltransferase polypeptide, which can be applied to the synthesis of human milk oligosaccharides (HMOs) and belongs to the field of enzyme engineering technology. The fucosyltransferase polypeptide described in the present application comprises a polypeptide having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, and 100% identical amino acid sequence to the polypeptide shown in SEQ ID NO:1-25. The transferase polypeptide described in the present application improves the ability of the polypeptide shown in SEQ ID NO:1 to catalyze the synthesis of 2'-FL while also improving the specificity of the polypeptide catalyzing the substrate.

The invention discloses a fusion protein, a fusion protein gene, a recombinant cell, a recombinant antigen, a reagent for detecting an anti-myelin sheath related glycoprotein antibody and a preparation method, a detection method and application of the reagent, the fusion protein is MAG, GlcAT-P and HNK-1ST fusion protein, and the MAG, GlcAT-P and HNK-1ST fusion protein is formed by sequentially connecting MAG, a GGGGS sequence, EGFP, P2A, GlcAT-P, T2A and HNK-1ST; the amino acid sequence of the MAG, GlcAT-P and HNK-1ST fusion protein is as shown in SEQ ID NO. 1; the kit can be used for detecting the MAG autoantibody, has excellent detection sensitivity and specificity, and can ensure the detection accuracy especially for the detection in a low titer range.